431 related articles for article (PubMed ID: 19078993)
1. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
[TBL] [Abstract][Full Text] [Related]
3. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy.
Ulasov IV; Tyler MA; Zhu ZB; Han Y; He TC; Lesniak MS
Int J Oncol; 2009 Mar; 34(3):729-42. PubMed ID: 19212678
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.
Kim CK; Ahmed AU; Auffinger B; Ulasov IV; Tobias AL; Moon KS; Lesniak MS
Mol Ther; 2013 Nov; 21(11):2063-73. PubMed ID: 23883863
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
[TBL] [Abstract][Full Text] [Related]
9. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats.
Sonabend AM; Ulasov IV; Han Y; Rolle CE; Nandi S; Cao D; Tyler MA; Lesniak MS
Cancer Gene Ther; 2009 Apr; 16(4):362-72. PubMed ID: 19011597
[TBL] [Abstract][Full Text] [Related]
11. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells.
Nandi S; Ulasov IV; Tyler MA; Sugihara AQ; Molinero L; Han Y; Zhu ZB; Lesniak MS
Cancer Res; 2008 Jul; 68(14):5778-84. PubMed ID: 18632631
[TBL] [Abstract][Full Text] [Related]
12. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.
Nandi S; Ulasov IV; Rolle CE; Han Y; Lesniak MS
J Gene Med; 2009 Nov; 11(11):1005-11. PubMed ID: 19688792
[TBL] [Abstract][Full Text] [Related]
13. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
[TBL] [Abstract][Full Text] [Related]
14. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
Ahmed AU; Thaci B; Tobias AL; Auffinger B; Zhang L; Cheng Y; Kim CK; Yunis C; Han Y; Alexiades NG; Fan X; Aboody KS; Lesniak MS
J Natl Cancer Inst; 2013 Jul; 105(13):968-77. PubMed ID: 23821758
[TBL] [Abstract][Full Text] [Related]
15. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
[TBL] [Abstract][Full Text] [Related]
16. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
Zhang J; Chen H; Chen C; Liu H; He Y; Zhao J; Yang P; Mao Q; Xia H
Cancer Lett; 2021 Jul; 509():26-38. PubMed ID: 33819529
[TBL] [Abstract][Full Text] [Related]
17. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation.
Thaci B; Ulasov IV; Ahmed AU; Ferguson SD; Han Y; Lesniak MS
Gene Ther; 2013 Mar; 20(3):318-27. PubMed ID: 22673390
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma.
Dey M; Yu D; Kanojia D; Li G; Sukhanova M; Spencer DA; Pituch KC; Zhang L; Han Y; Ahmed AU; Aboody KS; Lesniak MS; Balyasnikova IV
Stem Cell Reports; 2016 Sep; 7(3):471-482. PubMed ID: 27594591
[TBL] [Abstract][Full Text] [Related]
20. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.
Morshed RA; Gutova M; Juliano J; Barish ME; Hawkins-Daarud A; Oganesyan D; Vazgen K; Yang T; Annala A; Ahmed AU; Aboody KS; Swanson KR; Moats RA; Lesniak MS
Cancer Gene Ther; 2015 Jan; 22(1):55-61. PubMed ID: 25525033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
